QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) Starts Australian Observational Trial

VIVO Cannabis (TSX.V: VIVO) (OTCQX: VVCIF) today announced that it will begin an observational study on the use of cannabinoids as therapy for chronic pain. A group of well-known pain specialists will lead the study, taking place in Melbourne, Australia, which expects to provide long-term (24 month) data in order to evaluate the efficacy of medical cannabis in treating pain and further support development of VIVO’s portfolio of medical cannabis products. VIVO is funding the effort in the form of a research grant to its partner in the study, Australian Medical Cannabis Service (“AMCS”). “Driven by unmet clinical needs, medical cannabis products and treatment plans continue to gain momentum in Australia,” VIVO Chief Executive Officer Barry Fishman said in the news release. “The Study will help to inform VIVO’s product development through data gathered from both patients and physicians. This access to primary data is expected to continue to ensure our products address the specific health and wellness needs of our clients and customers, something that we believe provides distinct advantage. We remain committed to ensuring Australians have access to our medical cannabis, and to our efforts to change the way people view cannabis.”

To view the full press release, visit http://ibn.fm/uuPMu

About VIVO Cannabis(TM)

VIVO Cannabis(TM), based in Napanee, Ontario, is recognized for trusted, high-quality products and services. It holds production and sales licenses from Health Canada and operates world-class indoor cultivation facilities with proprietary plant-growing technology. VIVO has a collection of premium brands targeting unique customer segments, including Beacon Medical(TM), FIRESIDE(TM), Canna Farms(TM) and Lumina(TM). In August 2018, VIVO acquired Canna Farms, a premium cannabis company based in Hope, British Columbia. Canna Farms was B.C.’s first Licensed Producer and has several years of craft cultivation experience and expertise, as well as a significant patient base and positive cash flow. The Company is significantly expanding its production capacity and pursuing partnership and product development opportunities domestically, as well as in select international markets, including Germany and Australia. VIVO also operates Harvest Medicine, a patient-centric and highly scalable network of specialty medical cannabis clinics as well as a free telemedicine app. VIVO has a healthy balance sheet and is well-positioned to accelerate its growth in Canada and internationally. For more information, visit the company’s website at www.VivoCannabis.com.

NOTE TO INVESTORS: The latest news and updates relating to VVCIF are available in the company’s newsroom at http://ibn.fm/VVCIF